glp-1 obesity drug news updates Agonists Weight Loss Drugs Market Report, 2025-2030 Upcoming wave of hormone-based therapies

Discussing Pfizer's savvy acquisition of Metsera and critiquing the GLP-1 'gap analysis' many outsiders promote as a reason all the Big Pharmas will be in GLP-1

Liraglutide (3.0 mg, daily subcutaneous injection, n=22) or semaglutide (1.0 mg, weekly subcutaneous injection, n=18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%

But from 2030, Pfizer could emerge as a credible Top-3 obesity player if both the injectable and oral combo strategies succeed

Experts warn that misuse of Ozempic and Mounjaro could trigger serious health risks without medical supervision.